Department of Medical Oncology, CHU Liège, Liège, Belgium.
Department of Medical Oncology, CHU Liège, Liège, Belgium; Department of Gynecology and Obstetrics, CHU Liège, Liège, Belgium.
Cancer Treat Rev. 2024 Sep;129:102790. doi: 10.1016/j.ctrv.2024.102790. Epub 2024 Jun 22.
Until recently, patients diagnosed with locally advanced and metastatic endometrial cancer faced significant challenges in their treatment due to limited options and poor prognostic outcomes. The sequencing of tumors has been a major advancement in its management. It has led to The Cancer Genome Atlas classification currently used in clinical practice and the initiation of several clinical trials for innovative treatments targeting principally signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism. Numerous clinical trials are investigating a combinatorial approach of these targeted therapies to counter tumoral resistance, cellular compensatory mechanisms, and tumor polyclonality. This review provides a comprehensive overview of historical, current, and promising therapies in advanced and metastatic endometrial cancer. It particularly highlights clinical research on targeted and hormonal therapies, but also immunotherapy, reflecting the evolving landscape of treatment modalities for this disease.
直到最近，局部晚期和转移性子宫内膜癌患者在治疗方面面临着巨大的挑战，因为可供选择的方案有限，预后结果较差。肿瘤的测序是其治疗的一项重大进展。它导致了目前在临床实践中使用的癌症基因组图谱分类，并启动了几项针对主要信号通路、免疫检查点、DNA 完整性、生长因子、激素信号和代谢的创新治疗的临床试验。许多临床试验正在研究这些靶向治疗的组合方法，以对抗肿瘤耐药性、细胞代偿机制和肿瘤多克隆性。这篇综述全面概述了晚期和转移性子宫内膜癌的历史、当前和有前途的治疗方法。它特别强调了靶向和激素治疗的临床研究，但也包括免疫治疗，反映了这种疾病治疗方式的不断发展。
